Browsing Tag
Pfizer
121 posts
Nike taps Pfizer veteran David Denton as new CFO as Elliott Hill turnaround moves into execution phase
Nike names former Pfizer CFO David Denton as new finance chief with $20M package, signalling an execution-focused next phase under Elliott Hill. Read more.
Abivax (NASDAQ: ABVX) obefazimod NDA path meets a safety debate the market is still pricing
Abivax (NASDAQ: ABVX) put up Rinvoq-like ulcerative colitis remission data and dropped 40 percent. The question is whether the malignancy debate sticks.
Why Pfizer’s CFO exit raises fresh questions about debt, deals and obesity strategy
Dave Denton’s departure leaves Pfizer searching for a permanent chief financial officer while it works to integrate major acquisitions, reduce leverage and prove that its oncology and obesity investments can replace declining mature-product revenue.
HLN share price firms as Sensodyne and Centrum drive Haleon’s 2026 organic growth recovery
Sensodyne grows 8%. Centrum targets GLP-1 users. The £500m buyback erases shares at sub-340p. Haleon's recovery hinges on Q2 cold and flu normalising.
Insmed (NASDAQ: INSM) rebounds as retail eyes ATS 2026 readouts after Q1 reset
INSM bounced 11% after a 20% post-earnings reset. BRINSUPRI is launching faster than any respiratory drug in a decade. So why did the market sell the print?
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
Moderna faces fresh mRNA patent assault from CureVac as BioNTech tightens legal grip on COVID-19 vaccine royalties
Moderna just settled $950 million in mRNA litigation. Now BioNTech-owned CureVac wants Spikevax royalties too. The patent war is widening.
GSK locks in ViiV Healthcare majority as Shionogi doubles down and Pfizer exits with $1.8bn
GSK retains 78.3% of ViiV Healthcare as Shionogi doubles its stake to 21.7% for $2.125 bn and Pfizer exits. Read the full strategic analysis.
GSK wins FDA approval to extend Arexvy RSV vaccine to at-risk adults aged 18 to 49, opening 21 million-strong US market
FDA expands Arexvy approval to at-risk adults 18-49, opening 21M-strong US market. Read what this means for GSK, Pfizer, Moderna, and the RSV vaccine landscape.